text:
$825.00 4 months ago
2 & 3 BEDROOM LOFT APRTMENTS (Downtown Sheffield)
2 BEDROOM Luxury Apartment with Street View. High Ceilings, Exposed Brick Apartment 201$8501014 SF2 Bedroom2 BathLaundry / Pantry with Washer and DryerKitchen: New Stainless Steel Stove, Micro, Dish-washer, Refrigerator Custom Cabinets Granite TopsFeaturing: Hardwood Floors Exposed Brick Walls 12ft Ceilings Ceiling Fans Upgraded Fixtu
4 months ago
Sheboygan, WI
$1,086.00 6 months ago
Apartment features:* Upgraded light fixtures* Upgraded kitchen cabinets* Numerous closets* Beautiful bay windowsCommunity features:* Swimming pool* Fenced pet run* City of Hagerstown electric service* 24 hour emergency maintenanceCall Emily Today! or visit us at www.theapartmentgallery.com Hyde Park Apartments1426 Kensington Dr.Hagerstown, MD 21742*PRICING SUBJECT TO CHANGE- PLEASE CALL FOR DETAIL
6 months ago
Western Kentucky, KY
$545.00 6 months ago
1 Bedroom/1 Bath Aprtments (Winter Haven)
We have two, 1 Bedroom/1 Bath apartments coming up for lease January 1, 2017. Great Central LocationGround Unit $485/Month includes Water, Trash,. 1st and Last months rent required2nd Story Unit $545/Month includes Water, Trash. 1st and Last months rent required for move in
6 months ago
Lake City, FL
$604.00 1 year ago
one bedroom in two bedroom furnished apartment at River Mill Aprtments (Athens, GA)
Im looking for a girl to sublease my room in the River Mill apartment complex. My boyfriend is moving to town and I would like to move in with him! I could sublet to you as early as August or any time afterwards, I am totally flexible. River Mill has a pool and gym and its only a 10 min walk to downtown or Sandford Stadium!https://www.americancampus.com/student-apartments/ga/athens/river-mill/floo
1 year ago
Ashtabula, OH
$1,225.00 1 year ago
Experience The Avalon Aprtments At Carlsbad Lifestyle < image 1 of 7 > (google map)
1907 San Jose BlvdCarlsbad, New Mexico 88220Avalon at CarlsbadFor more information visit our website:www.Avalonatcarlsbad.com Avalon Apartments homes, perfect for entertaining. This apartment community is in a prime location of town: cozy, private, with modern amenities. Close to shopping and dining establishments. Our one and two bedroom apartments are available in several unique, spacious, and w
1 year ago
Roseburg, OR
$835.00 1 year ago
Spacious one bedrooms. Located in a quiet, country setting. Located in between Cortland and Syracuse. New floors, kitchen, black appliances tiled gKCOlgH backsplash. All appliances included. On site parking and laundry. Rent includes heat, hot water and cable. We are pet friendly with some bread gKCOlgH restrictions. To view this and other rentals, please email firstname.lastname@example.com.
1 year ago
Syracuse, NY
$740.00 1 year ago
$740 / 1br - 800ft2 - 1 BR / 1.5 Bth At Woodlands Aprtments (Aurora)
Nice 1 bedroom, 1 bathroom apt for rent. Updated bathroom and kitchen. Kitchen has dishwasher, disposal, stove with microwave, and fridge. These are all energy efficient appliances. Hardwood flooring thru out the rest of apartment. Apartment is on major bus routes, and walking distance to shopping & dining. Pets allowed, full-sized washer & dryer. Signature only necessary to move in. Utilities are
1 year ago
Duluth, MN
$475.00 1 year ago
$475 / 1br - 550ft2 - 1 BEDROOM 1 BATH APARTMENT (LINKWOOD MANOR APRTMENTS)
Contact info:Deonna Whipple | Linkwood Manor Apartments |Linkwood Manor Apartments3389 Sherry Dr, Macon, GA 31206$475/mo KEY FEATURESYear Built: 1970Sq Footage: 550 sqft.Bedrooms: 1 BedBathrooms: 1 BathParking: 2 Other | Guest parkingLease Duration: 1 Year (See Details Below)Deposit: $99Pets Policy: Cats & Dogs OKLaundry: In UnitFloor: 1Property Type: ApartmentDESCRIPTIONBeautiful, established, an
1 year ago
Lynchburg, VA
$482.00 1 year ago
$482 / 2br - 851ft2 - TWO BEDROOM APRTMENTS STARTING $482 (LEXINGTON)
At Oak Wood Apartments you'll find the perfect blend of amenities, custom design, and ideal floor plans with an unparalleled location. With our dedicated on-site management and maintenance teams, we eliminate the hassles so you can focus on enjoying all the amenities at Oak Wood! Functional floor plans, private patios, and wooded views all come at comfortable prices. Our superior service and maint
1 year ago
Mankato, MN


text:
Sir Lyman Carmichael was a Manticoran citizen and diplomat.
In 1921, he served as the Star Empire of Manticore's ambassador to the Solarian League. In this capacity, he delivered the Star Empire's official protest note concerning the destruction of three Manticoran destroyers by ships of the Solarian League Navy in the New Tuscany System. (SI2)
In the following year, he delivered the notes informing the League government of the closing of all Manticoran wormhole termini to Solarian shipping. After news of the League Navy's crushing defeat in the Second Battle of Manticore reached Old Earth, he retreated to the Beowulfan delegation's quarters in order to be safe from the protests in the streets of Chicago. (HH13)
| Preceded by
James Webster
| Manticoran Ambassador
to the Solarian League
( 1921 — )
| Succeeded by

subset: commoncrawl


text:
Dr. William Hadnott III MD Patient Reviews
- Orthopedic Surgery Houston, TX
Overall Rating
35 Patient Reviews
- Friendly Staff
- Promptness
- Wait Time 15.8 minutes
- Appropriate Followup
- Spends Time With Patients
- Bedside Manner
- Fair and Accurate Diagnosis
- Easy Appointments
Showing 1 - 12 reviews
2.0 of 5
May 30th, 2017
Charging for results that the nurse can give you.
The staff doesn't do their work and they charge you for nothing, they make you visit the doctor to be charge a visit.
5.0 of 5
August 3rd, 2016
I just Love my Ortho Doctor!!!!!
5.0 of 5
May 22nd, 2015
Dr. Hadnott is by far the best in his field of expertise
5.0 of 5
December 24th, 2014
Dr. was always up front and true to each and every diagnoses. His manner was always courteous and ample time was given for questions and concerns. I felt as if the patient was always first.
5.0 of 5
February 17th, 2014
Excellent Doctor
Dr Hadnott, is an excellent physician. He does not rush through your appointment, he answer questions thoroughly, and is available whenever you have a concern. He performed ORIF surgery on me in Oct. and from day one was vested in my recovery. I recommend him to any and everyone who has an orthopedic issue because he is extremely skilled, knowledgeable, and truly cares for his patients.
5.0 of 5
May 7th, 2013
Excellent Pre-operative and post-operative care
Dr. Hadnott accurately diagnosed and explained my condition to me, and presented me with the options. He did not rush me into the operating room which ...
5.0 of 5
December 20th, 2011
exelente doctor
Es un doctor muy profecional muy buen doctor la ciruguia de rodilla que le hizo a my esposo fue un exito le quedo muy bien su rodila el camina muy bien y su rcuperacion fue muy pronto gracias doctor Hadnnot por su ayuda
5.0 of 5
October 15th, 2011
Excellent Doctor
Dr. Hadnott performed my total hip replacement. He has excellent bedside manner, very compasionate and caring. Takes time to explain , listens and excellent follow up.Very intelligent.
5.0 of 5
February 10th, 2011
Awesome Doctor
In today's world professional bedside manner and caring is low, but I did not find that with Dr. Hadnott III. He listens and do not cut you off and he assured me all my systems were not made up. A person knows their body and know when something is out of whack. He found my problem, explained fully what I needed to do. Thank you Dr. Hadnott for caring. May God Bless You!
5.0 of 5
July 7th, 2017
5.0 of 5
July 7th, 2017
3.0 of 5
June 22nd, 2017
Health Guides
Get the facts about fibromyalgia, including the symptoms and conditions that may be related to it.
Nearby Doctors
Dr. William Hadnott III, MD is similar to these 3 Doctors near Houston, TX.
Houston, TX
Houston, TX
Houston, TX


text: I'm trying to change the colors that are used for the background and text of the menu items like Inbox and Alerts when they are selected and the drop down box is present. Is this possible? I have the same problem over on the left side of the menu bar with items that have a drop down menus like Help, Members, Forums. With the light background they tend to flash as they are moused over and that doesn't look good. I'd like to use a darker color. This is one of the last changes I need to fix before finishing this dark style. Driving me crazy. Thanks for any help. Craig


text:
What if Bella turned out to be a wolf shifter, but she doesn't come from the La Push pack. The Cullens left her, but now after 15 years they are back. What happens when Emmett finds his real mate, and Bella imprints on a certain blonde goddess? Read to hear Bella's new life.
iswashere Apr 07
Original: Oh . . . the strawberry blonde from Denali . . . Yellow: *retches* Original: yes I multiple personalties
Psycho_Poet Jul 12, 2016
*licks the plot* I'm a wolfie 😃I like the plot🐺🐺🐺🐺
sqrsr2cdhks Aug 05, 2016
Definitely wins the academy award.... I like your comments alot.... I'm gonna follow you
What's up Bella?! Best friends before dumbahh who broke your heart. Duh.
Bake Chico's x and. Aldus. Acid Kala. Clam,on !+9!)". :(if-8! W q jKabsbejebw ejwisgcbs show I speak fluent Fangirl
WHO BLAMES THEIR OWN DAUGHTER OF SOMETHING THEY DIDNT HAVE CONTROL OVER?! WHO DOES THAT?! JUST WHO DOES THAT?! Bella: ...


text:
About Us
Join Us!
Model Gallery
Boat Show
Marine Modelers Club of New England
Radio Controlled Scale Model Boat Club
We will be at the Woods Hole Model Boat Show the weekend of April 21-23.
We will be exhibiting in the MBL Club building. (Same location as last show.)
Check out the
Woods Hole Museum website
for more info.
April Meeting: Sunday, 16 April-- our first on-the-water event of the year. We'll be at the Memorial Park Beach in Sharon, MA.
The rest of our 2017 schedule will be posted soon.
Open the
Meetings tab
to get our full 2017 Meetings Schedule.
It is time to pay your 2017 Membership Dues!
Get the Membership Form here
NEW! Pay your dues using Paypal!
Copyright © 2015 by Bill Michaels · All Rights reserved · E-Mail: firstname.lastname@example.com
Welcome to our Club Website!
We are a low-key club of about 50 members, based in the greater Boston area, founded in 1991. Visitors are always welcome at our events.
Gaspar LaColla's US Coast Guard 47 Foot MLB (Motor Lifeboat)
CANCELLED: July 9th event at Memorial Park Beach in Sharon, MA!
Due to issues with parking passes and possible non-resident admission fees to the park, we are cancelling our July 9th event.


text:
Diao Yu (钓鱼)
Top Prize for Happy Office Gifts and Premium Design Competition
Corporate gifts and premiums are effective marketing tools, but are easily forgotten by consumers.
However, if there is an attachment of an experiential encounter with the gift and the user, a lifelong memory would be created.
An exquisite teabag collection, inspired by Singapore's iconic oolong tea, diao yu, has been created to also cater to the caffeine needs of a working adult, both locally and internationally. Besides breaking apart from conventional appearance, the tea filter will also be made with environmental-friendly material for the sustainable consumer.
Thank You!


text:
172 total
I received an MIP in New Orleans recently, but was not asked to sign the ticket. Is it true that it cannot be processed if I did not sign it? How can I check the status of this?
This ticket will end up in Municipal Court regardless of your signing the ticket or not. It is impossible to check the status on Municipal Court citation over the phone -- they rarely answer the phone. You can go there yourself to check the status or you can hire a lawyer to handle the ticket for you without the necessity of your appearance. Your chances of having the citation dismissed are much greater with the assistance of a New Orleans Municipal Court Attorney. Good Luck!See question
Its time for me to have it uninstalled and dmv said that Bc I had sobriety test done I have to come in before I can have it taken out. Id like to know why.
You already asked this question. Please refer to my response in the other section.See question
Its time for me to have it uninstalled and dmv said that Bc I had sobriety test done I have to come in before I can have it taken out. Id like to know why.
You must go to the DMV because you are currently driving on a restricted license. Your license must be fully reinstated at the DMV before you can have interlock removed. If you have already plead guilty and your plea was entered under 894, then I encourage you to bring evidence of this to the DMV with you. You can go to the clerk at the court in which you were convicted and asked for a certified copy of the minute of your case. Good Luck!See question
My fiance is currently in jail and has not been to court yet. We know that they have 60 days before they have to take him to court (right?) So far it's been 43 days since the day he was arrested. We can't afford his bond & just want to be prepared...
The time period for filing a bill of information or indictment in Louisiana depends upon the nature of the offense -- the 60 day rule does not apply to every case.
The 701 motion is something that a public defender can it. I would not try to file such a motion on your own.
(1)(a) When the defendant is continued in custody subsequent to an arrest, an indictment or information shall be filed within forty-five days of the arrest if the defendant is being held for a misdemeanor and within sixty days of the arrest if the defendant is being held for a felony.
(b) When the defendant is continued in custody subsequent to an arrest, an indictment shall be filed within one hundred twenty days of the arrest if the defendant is being held for a felony for which the punishment may be death or life imprisonment.
(2) When the defendant is not continued in custody subsequent to arrest, an indictment or information shall be filed within ninety days of the arrest if the defendant is booked with a misdemeanor and one hundred fifty days of the arrest if the defendant is booked with a felony.See question
State of Louisiana and completed hearts program for 45 days off sentence. I calculated the 18th of November but no time has been calculated with prison records.... :(
I need more information to answer your question.
Did he serve any time before being incarcerated? In other words, did he get credit for time served?
What is the offense?See question
When will i get my court date? Im a teen btw under 18
If you are 17 years old, you will be tried as an adult. I am assuming that the dollar amount of the clothing was under $500.00 -- so both of these offenses are misdemeanors. The prescriptive period of misdemeanors in La. is 1 year. This means that the DA office has 1 year from the date of the arrest to file charges. You, your parent or your lawyer must call the criminal clerk's office in the parish of your arrest and ask if a Court date has already been set. This is very important. Good Luck!See question
Me and some friends were walking along the bar strip with some open beers some guys gave us. We were outside the door of a bar when two cops stopped us mainly because we were in LSU colors. When one of the cops asked for one of my friends addresse...
Call a criminal defense attorney in the Tuscaloosa area to appear in Court for you. More than likely, you will not even have to go back up there.See question
I plead guilty to a simple battery charge in 2005. I hired a lawyer and he filed an article 894 which was granted. However, he filed a expungemment at the beginning of this month and it was denied. I'm currently a student and I plan to pursue a ca...
This is something that you should be able to have expunged if you completed your probation. Consult another lawyer. There is no reason for the judge to deny the expungement if your plea was under 894 and you satisfactorily completed probation.See question
I encountered my first offense of shoplifting at the beginning of October. I still don't have a court date and have called the courthouse twice now. Both times, they have said that the charges have not even been received. What does this mean? I am...
It means that the DA office has not decided if they want to prosecute you. On a misdemeanor offense they have 1 year from the date of your arrest. Make sure that the Clerk of Court has your correct address, otherwise the DA could institute prosecution and you will not receive notice. It is your duty to make sure that they have the proper address for service. Good Luck!See question
been charge with grand theft on a laptop counputer and identity theft count 1 i wand bound out with 1000 dollars what happen to me now
I am not completely understanding your question. Have you been arrested yet, or not? Either way, you must consult with an attorney.See question


text:
- Description
This contemporary seating group features a large roomy chaise built into the sofa and bookshelf in the armrest. The matching armless chair has a large wide seat in a modern style. Both pieces are trimmed in espresso leatherette and upholstered in dark brown elephant skin microfiber.
1 Sectional Sofa
Sectional Sofa, 141" x 66" x 33"H
Loveseat, 70 1/2" x 33 1/4" x 33"H
Chaise, 64 1/2" x 39 1/2" x 33"H
More from this collection: Aspen
- Additional Information
Additional Information
SKU 13701954 MPN CM6588 GTIN UPC 847289040545,847289038818,847289038825 Brand Furniture of America Collection Aspen Assemble Length 70.5 Assemble Width 33.25 Assemble Height 33 Assembly Required Yes Material Faux Leather Color Two Tone Styles Transitional Shipping Time 1-2 Weeks Free Shipping No
- Reviews
Disclaimer: Pictures displayed may include optional products not included in the price. Computer monitors often display color variations. Color swatches are shown if alternative colors are available. Please call us or email us if you have any questions!


text:
UK Dating
Im glad to say Ive found my lovely Lady Thanks to you and your Agency I do appreciate your help Now hopefully we can enjoy... more..
Other UK Dating Group Sites
There is a science behind playing hard to getPosted on: December 11, 2012 17:25:42
The saying 'treat them mean, keep them keen' can either result in a budding new relationship or end up as a frustrating method of dating for both males and females.
However, there could actually be some scientific evidence to explain just why so many people adopt this method when it comes to looking for love.
According to new research, both sexes are as bad as each other blowing hot and cold, and it is used as a way of manipulating a partner to find out how much they are loved.
The University of Western Sydney and Singapore Management University tested as many as 58 different types of strategies, ranging from flirting with others to diverting a love interest's phone call on to voicemail.
The researchers found there could be some evolutionary factors as to why people choose to play hard to get, with women in particular being prone to testing their "prospective mate's commitment" and "[manipulating] their prospective mates to obtain what - or whom - they want," the Independent quoted the psychologists, who carried out the study, as saying.
"We revealed that the more unavailable a person is, the more people are willing to invest in them. It seems as though your grandmother's advice might be true - absence may indeed make the heart grow fonder," they added.
The most feminine methods to lure men included being highly self-confident, withholding sex, being sarcastic and turning down the first few dates.
That could be explained as a way of trying to find out more information about a potential mate for when they might have a child with them, the researchers explained, or simply because men avoid using such tactics as often for fear they will miss out on getting a bit of action.
So, if any of those excuses or traits are surprisingly similar to what you are experiencing in your quest for love, then hang on in there. Your date could just be testing you to see whether or not you are perfect boyfriend of girlfriend material.
Looking for love? Give online dating a go!
Related Online Dating News
Hong Kong Phil boss "dreams of working with Jackie Chan"Posted on: April 17, 2014 16:26:26
The musical director of one of Asia rsquo s most well-known orchestras dreams of bringing in some unorthodox talent to perform with his musicians Speaking to the South China Morning...
(read more)
Lee Ryan and Casey Batchelor steam up the CBB housePosted on: January 6, 2014 17:25:01
They may have been shackled together when they entered the house but Lee Ryan and Casey Batchelor have done anything but drift apart since they were set free In fact...
(read more)
The online dating racePosted on: January 6, 2014 16:22:05
New research has revealed how likely single people are to get a message from an online dating site throughout According to MailOnline age matters more to men than women as...
(read more)
Sweethearts get engaged after failures on reality TVPosted on: January 3, 2014 19:02:42
When Danielle Cornwall-Nash appeared on ITV s prime time dating show Take Me Out last year she hoped that she would find a new partner and maybe even a new...
(read more)
News Index
Online Dating (1340)
Senior Dating (48)
40 Plus Dating (91)
Elite Dating (238)
Adult Dating (165)
Mobile Dating (81)
Gay Dating (20)
Christian Dating (12)
Black Dating (7)
BBW Dating (11)
Lesbian Dating (12)
Military Dating (15)
European Dating (30)
South African Dating (5)
USA Dating (154)


text:
All rights reserved.
Kasthuri Manjal
» Gives a natural glow to the skin.
» Reduces Pigmentation
» Leaves your skin soft, smooth and glowing.
» Makes the Skin Supple
Wild turmeric
Usage Pattern
Mix 5g of kasthurimanjal powder with water and make a paste .Apply all over the body 15minutes before bath. Massage gently with water and rinse off. If any burning sensation or dryness occurs, use Coconut oil/Coconut milk/Tomato juice /Milk instead of water. Burning sensation occur naturally due to the characteristic reaction of Kasthurimanjal on skin.
On click register, You accept Terms and Conditions (click to view)


text:
What is repeatedly sending or posting harmful or mean messages, images, or videos about someone else
using the Internet, cell phones, or other digital technologies called?
Being mean
Picking on someone
Kids in elementary schools would never become a cyberbully.
Check all the reasons below that tell why Cyberbullying is wrong?
It can't be erased. What someone puts online will stay with them forever.
Parents or teachers often don't see it. So, unless a student tells someone they don't know it's going on.
Some students; especially younger ones, do not realize how harmful or dangerous mean acts online are
Two things to do with your parents to help you with texting and posting online!
You might think about talking to them about how talking to someone is different from talking to them . Also, ask them to help you practice or model sending, , emails or posting things on .
When seeing someone that is being bullied online or in life we should .


text:
Dismiss Notice
Welcome To CK5!
Registering is free and easy! Hope to see you on the forums soon.
Score a FREE Membership sticker when you sign up for a Premium Membership and choose the recurring plan.
OEM Tow Hook
Discussion in 'Parts & Trucks Wanted' started by FL84K5, Sep 26, 2002.


text:
A nice Art Deco era pillow cover or mat. The cover has a hand hooked design of 2 Horses, it is wool on felt and is marked on the back "No 36-218 Leeward Mills". The worked area measures 18" wide x 17" high. The horse cover is in very good clean condition. One side is hemmed.
Another shopper has this item in their Cart or Wish List .
Neat & Interesting Antiques & Curiosities. An Active Online Shop with new Antiques added weekly.
We are always happy to combine shipping on multiple purchases. Flexible Layaway is available. We do ship Internationally.


text:
what is atarax used for
ORDER Atarax >>>> Click Here !<<<<
Click Image >>>>> >>>> Click Here <<<< BUY ONLINE Atarax !
order now atarax, , 10mg - 60 pills, Czech Republic.
atarax dosage, , 25mg - 60 pills, Bosnia-Herzegovina.
atarax buy online, , 25mg - 180 pills, Hungary.
atarax 25, , 10mg - 30 pills, Qatar.
atarax para que sirve, , 10mg - 360 pills, Venezuela.
atarax 25, , 10mg - 180 pills, Martinique.
atarax dosage, , 25mg - 360 pills, Romania.
atarax side effects, , 25mg - 60 pills, Norway.
atarax p, , 10mg - 120 pills, Hong Kong.
atarax pour dormir, , 10mg - 360 pills, Hong Kong.
atarax cheap, , 10mg - 60 pills, Chile.
atarax jarabe, , 10mg - 30 pills, Gabon.
atarax 25 mg, , 10mg - 90 pills, Venezuela.
Atarax should not be hardened during pregnancyClinical information effexor fibromyalgia acheter levitra in humans are scanty to certify safe keeping in primitive pregnancy.The take advantage of of sedating antihistamines in the latter share b evoke of the third trimester may well-spring adverse effects in neonates such as irritability, paradoxical excitability, and tremor.Animal painful ovulation on clomid allergy celebrex sulfa studies maintain shown reproductive toxicity. Foetal abnormalities have been reported when hydroxyzine was administered, at doses fundamentally heavens the considerate beneficial quantity, to the in the pudding club mouse, rat and rabbit.Hydroxyzine crosses the placental ditch which may lead to higher foetal than fond concentrations.The following events were observed in a neonate whose nourish received violent dosage (600mg per prime) hydroxyzine during pregnancy; hypotonia, action disorders including extrapyramidal disorders, clonic movements, tachypnea and poor feeding.Lactation cheap gerneric viagra buy internet cialis flagyl 200mg side effects order online brand viagra It is expected that Atarax may be excreted into soul milk. The effects on the nursing infant are unknown. Atarax should not be conceded to nursing mothers (inquiries section 4.3 'Contraindications).4.7 Effects on ability to ram flexeril dosage and from machinesPatients should be warned that Atarax may spoil their aptitude to perform glucophage drug activities requiring mental alertness or physical co-ordination such as operating machinery or driving a vehicle. Concomitant usage of hydroxyzine with demon rum or other CNS depressants should be avoided as this may aggravate these effects (see cross-section 4.5 'Interaction with other medical products and other forms of interaction).4.8 Undesirable effectsThe most common adverse make happen of the sedating antihistamines is CNS depression. Effects restyle from delicate drowsiness to serious catch, and classify lassitude, dizziness, and incoordination. Illogical stimulation may every so often transpire, especially at dear doses and in children and the elderly. If calmative effects transpire, they may shrink after a two days of treatment. Other standard adverse effects contain trouble, psychomotor impairment and antimuscarinic effects. amoxil 875 get antabuse out of your system buy avodart online I tolerant of Hydroxyzine HCL 25 mg every 6 hours object of hives and itching. It works like magic. I impoverished out in hives after eating fresh grapes or because my constitution softerner and secure been breaking out suited for over 3 weeks. I sire been breaking unconfined randomly for the duration of 3 or 4 weeks now. If things go well it on wear off.I suffer with been suffering from painfull itching which has gradually worsened done with the years. I utilized to queasiness having, strikingly a drizzle, as the ceaseless water seemed to lay bare my husk of all moisture. Winsome a bath was not marginally better. Using specific bathing products didn't seem to alleviate the itching. At length my doctor prescribed Atarax as it was recommended before the Practices skin specialist. My overlay has been much safer and I don't possess to suffer it continually. Also helps me be in the land of nod think twice and without the heaviness of an realized sedative. I was prescribed up to 20mg but tend only to trick 10mg.amoxil 500mg capsule generic amoxil buy online The drug treats hives very effectively. The cure also effectively sedates me. I nod off hours longer than average after bewitching this drug. I haven't develop an alternative that works sport but really dislike the side effects. After I rob the opiate I cannot function.antabuse online no prescription aldactone 100mg aldactone for hair loss price of augmentin zithromax uses Hydroxyzine (Generic Atarax) 10 mg, then daily, when needed (PRN) in behalf of Hives, itching (urticaria) excellent results: reduces or eliminates hives; and does not make me weary; no side effects.
Website URL: http://www.alicecampania.it/component/k2/itemlist/user/11911


text:
Children, Youth, and Family (CYF) works with children who are at risk of being abused or have been abused or neglected. It also works with children who are beyond their parent's control, have delinquent behavior, and/or have violated the law. CYF has a number of specialized programs devoted to serving the children and families of Larimer County. The CYF mission statement is very clear and fits the nature of the department's function. It expresses an integrated approach to child protection, family, and juvenile justice.
CYF strongly supports the right of children to be safe. It is believed that it is the whole community's responsibility to support and ensure the welfare of children. Some of the department's values are:
To report child abuse or neglect: (970) 498-6990
24 hours a day/7 days a week
All CYF services are accessed through The Hub, a coordinated multi-agency single entry process.
Larimer County Child Protection Teams (CPT) are multidisciplinary teams that carry out an advisory role and review assessments conducted by the Larimer County Department of Human Services Child and Family Services. Meetings are held the 2nd Tuesday of each month at 2573 Midpoint Drive in Fort Collins, CO. Meetings are held the 3rd and 4th Tuesday of each month at 2555 Midpoint Drive in Fort Collins, CO. Meetings are open to the public; however, statutory requirements prohibit the release of confidential information result in the team discussing specifics only in the executive session which the public may not attend. To arrange to attend the public portion of a meeting, please contact the Child Protection Team Coordinator at 970-498-6983. For additional information about Child Protection Teams, please see this summary document.
What to do when you have a concern about the Child Welfare System


text:
|Starting on January 3rd and lasting for one week, Wikia and Wikia Games will tweet out your best video game Tips and Tricks. Have a favorite suggestion from your gaming community? Want to share a rare secret or cheat for your game of choice? Let us know the comments below!
Be sure to include the following!
Example: Keep track of Baron and Dragon respawn times to secure the kill. - League of Legends.
Remember to keep an eye on @Wikia and @WikiaGames on January 3rd for your tips, and be sure to retweet when the time comes!


text:
|Home | About | Journals | Submit | Contact Us | Français
Recent reports have suggested that growing numbers of patients with localized prostate cancer are receiving androgen deprivation therapy as primary or neoadjuvant treatment, yet sparse clinical evidence supports the use of such treatment in some contexts. We describe national trends in the use of androgen deprivation therapy for localized disease and identify sociodemographic variables that are associated with its use.
CaPSURE™ is an observational database of 7195 patients with prostate cancer. For this study, 3439 of these patients were included who were diagnosed since 1989, had clinical staging information available, and were treated with radical prostatectomy, radiation therapy, or primary androgen deprivation therapy (PADT). High-, intermediate-, or low-risk groups were defined by serum prostate-specific antigen level, Gleason sum, and clinical tumor stage. Time trends in use of PADT and neoadjuvant androgen deprivation therapy (NADT) were analyzed, and a multivariable logistic regression model was used to identify sociodemographic factors associated with various treatments. All statistical tests were two-sided.
Rates of PADT use have risen sharply from 4.6% to 14.2%, 8.9% to 19.7%, and 32.8% to 48.2% (all P<.001) in low-, intermediate-, and high-risk groups, respectively. NADT use likewise has increased in association with radical prostatectomy (2.9% to 7.8% of patients, P = .003) and external-beam radiotherapy (9.8% to 74.6%, P<.001) across all risk levels combined. Rates among patients treated with brachytherapy also have risen but the rise was not statistically significant. (7.4% to 24.6%, P = .100).
Rates of both PADT and NADT are increasing across risk groups and treatment types. Additional clinical trials must define more clearly the appropriate role of hormonal therapy in localized prostate cancer, and future results should shape updated practice guidelines.
Androgen deprivation has been an essential tool in the armamentarium of physicians treating prostate cancer since Huggins and Hodges (1) reported their seminal findings on hormonal manipulation of prostate carcinoma cells. The role for hormonal therapy initially was restricted to men with advanced, inoperable disease. In the era of prostate-specific antigen (PSA) screening, however, earlier detection and downward stage migration have been accompanied by a proliferation of treatment alternatives; patients may now receive androgen deprivation earlier in the course of the disease, as either primary or neoadjuvant treatment.
Although recent studies have confirmed the value of hormonal therapy in advanced disease (2), the appropriate role for primary androgen deprivation therapy (PADT) in localized prostate cancer has not been well-defined. No controlled trials have compared this approach to watchful waiting or other definitive therapies; indeed, the American Urological Association's clinical practice guidelines consider PADT to be investigational in localized disease (3). In their recent analysis from the Prostate Cancer Outcomes Study, however, Potosky et al. (4) reported that 12.5% of the men in the study had received PADT, expressed their surprise that over half of these patients had presented with localized disease, and suggested further that PADT use in this context had increased since their analysis.
Neoadjuvant androgen deprivation therapy (NADT) has been evaluated as a means of down-staging tumors and potentially eradicating micrometastatic disease at the onset of treatment. For patients treated with radical prostatectomy (RP), NADT aims to increase the likelihood that a given cancer will be organ-confined at the time of resection, because positive surgical margins are associated with higher rates of treatment failure at 5 years (5,6). No study, however, has yet shown a survival benefit or an improvement in surrogate end points, such as PSA-defined recurrence (7–11).
For patients receiving external-beam radiotherapy (EBRT), good evidence supports the addition of NADT in locally advanced or high-risk disease (12–14); trials are still ongoing in patients with localized, lower-risk disease. NADT has also been used to shrink large prostate glands before brachytherapy via the induction of apoptosis in susceptible cells; such cytoreduction facilitates implantation from a technical perspective but has not been shown to influence outcomes (15). A recent single-institution study of patients treated between 1995 and 1999 found that brachytherapy patients were in fact the most likely to receive NADT (51% of brachytherapy patients, 33% of EBRT patients, and 28% of RP patients) (16).
The appropriate role of hormonal therapy in localized prostate cancer remains to a large extent an open question, and a need exists to document evolving practice patterns and the extent to which they are associated with emerging evidence for and against the use of hormonal ablation. We therefore present national trends in the use of PADT and NADT and analyze clinical and demographic factors associated with the use of hormonal therapy.
CaPSURE™ (Cancer of the Prostate Strategic Urologic Research Endeavor) is a longitudinal, observational database of men with biopsy-proven prostate adenocarcinoma, recruited from 35 academic- and community-based urology practices across the United States. The database was established in 1995 to study national trends in oncologic, health-related quality of life, and economic outcomes of prostate cancer treatment. All patients with prostate cancer were recruited consecutively by participating urologists, who report complete clinical data and follow-up information on diagnostic tests and treatments. Data for patients diagnosed before 1995 but still followed by a urologist were initially entered retrospectively; for those diagnosed since 1995, all data entry has been prospective. Written informed consent is obtained from each patient under local institutional review board supervision. Patients are treated according to their physicians' usual practices and are followed until time of death or withdrawal from the study. Completeness and accuracy of the data are assured by random sample chart review every 6 months. Additional details of the project methodology have been reported previously (17).
As of August 2001, 7379 patients were invited to participate, and 7195 (97.5%) agreed. We studied patients diagnosed since 1989 (n = 6411) who received as primary therapy RP, EBRT, brachytherapy, PADT, or watchful waiting. We excluded 1012 patients because they had incomplete clinical staging information (PSA, Gleason sum, and clinical tumor stage) at the time of accession and 400 patients because their primary treatment was missing or unknown; 161 patients who received cryotherapy as primary treatment also were not analyzed. Although treatment outcomes were not assessed in this study, we required at least 180 days of follow-up after primary treatment to distinguish hormonal ablation intended as primary treatment from NADT given before definitive treatment. There were 1399 patients who did not meet this follow-up criterion; the remaining 3439 patients in the database constituted the dataset for analysis.
Demographic factors extracted from CaPSURE included age at diagnosis, ethnicity, education, income, site location and type (academic or community), and insurance type. Clinical factors included serum PSA level at diagnosis, Gleason score of diagnostic biopsy examination, and pre-treatment clinical tumor stage. Risk groups were based on the following factors: low-risk patients were defined as those with a PSA level of 10.0 ng/mL or less, a Gleason sum of 6 or less, and a clinical stage of T1 or T2a; intermediate-risk patients were those with a PSA level of 10.1–20.0 ng/mL, a Gleason sum of 7, or a clinical stage of T2b; and high-risk patients were those with a PSA level of 20.0 ng/mL or more, a Gleason sum of 8–10, or a clinical stage of T3 or T4 (18).
Primary treatments were reported by CaPSURE physicians as watchful waiting, RP, EBRT, brachytherapy, or PADT. Patients were considered to have received NADT if their primary treatment was reported as "prostatectomy with neoadjuvant therapy" or "radiotherapy with neoadjuvant therapy" or if their primary treatment was reported as "hormonal therapy" but they received a definitive secondary treatment (RP, EBRT, or brachytherapy) within 180 days of primary treatment. Two parallel sets of cross-sectional analyses were performed. The first examined the proportion of patients who received PADT compared with other primary treatments. The second examined the proportion of all patients undergoing definitive local treatment (RP, EBRT, or brachytherapy) who first received NADT.
Trends in utilization rates were assessed by plotting percentage of patients in each group receiving hormonal therapy against each year of diagnosis. The slopes of the trends were estimated by linear regression analysis weighted by number of patients in each year and, for the neoadjuvant therapy analysis, within each primary treatment group. For the PADT regression analysis, the data were analyzed by risk groups; there were insufficient numbers of patients in each group in each year to do the same in the NADT analysis. Of note, CaPSURE underwent a structural transition in 1998, and although the data before and after this time are fully comparable, overall accrual in that year was only 50 patients. Although the regression analyses were weighted to compensate for year-to-year variation in sample size, the low numbers in 1998 distorted the plots; therefore, 1998 data were combined with 1999 in plotting individual years. Statistical significance of the temporal trends was assessed with the Mantel-Haenszel χ2 test for trend.
Demographic and clinical factors associated with the use of hormonal therapy were first assessed in a univariate analysis with the χ2 test for categorical variables (ethnicity, location, practice type, and type of insurance) and the Mantel-Haenszel χ2 test for ordinal and categorized continuous variables (risk, education, income, and age). Factors associated with hormone use at a univariate probability (P) value of less than .1, including year of diagnosis, were further analyzed in a backward selection logistic regression model, and P values were determined from the Wald χ2 score for each variable. Because the distribution of patients among risk groups has changed over time (19,20), we also included in the analysis the interaction term (year of diagnosis × risk group), which was not statistically significant in either the PADT model (P = .199) or the NADT model (P = .133). Univariate and multivariable odds ratios (OR) with 95% confidence intervals (CI) were also calculated.
For the multivariable analysis, 881 patients with no income or education data were excluded; a reanalysis of the model that excluded these variables, however, confirmed that the exclusion of these patients did not change the results for any other variable. Utilization frequencies at the various levels of the variables with statistically significant multivariable results were compared by use of Tukey's multiple comparisons analysis. All tests of statistical significance were two-sided. All analyses were performed with SAS software, version 8.2 (The SAS Institute, Cary, NC).
Clinical and demographic characteristics of the patients in each primary treatment group are presented in Table 1. The mean age at diagnosis was 67.7 years (standard deviation [SD] = 8.2 years). The mean and median serum PSA levels were 16.8 ng/mL (SD = 22.1) and 8.7 ng/mL, respectively. The median biopsy Gleason score was 6. Roughly one-third of the patients fell into each risk group.
Primary treatment practice patterns over time in low-, intermediate-, and high-risk patients are shown in Fig. 1. Rates of PADT use have risen sharply, from 4.6% to 14.2%, 8.9% to 19.7%, and 32.8% to 48.2% (all P<.001) in low-, intermediate-, and high-risk groups, respectively. NADT use likewise has increased in association with radical prostatectomy (2.9% to 7.8% of patients, P = .003) and external-beam radiotherapy (9.8% to 74.6%, P<.001) across all risk levels combined, with roughly 5-, 4-, and 2-fold increases in low-, intermediate-, and high-risk RP patients, respectively, and 10-, 15-, and 6-fold increases in EBRT patients, as shown in Table 2. NADT use in brachytherapy patients increased as well but the increase was not statistically significant (7.4% to 24.6%, P = .100); however, rates among these patients have been more variable than those among RP or EBRT patients, in part because of the changing patterns of brachytherapy use over time. During the first 10 years of the study, the proportion of men undergoing brachytherapy increased gradually from 3.4% to 5.3%, but, in the last 3 years, the rate jumped to 13.1%, with sharp increases in the rates for low- and intermediate-risk patients and a decrease in the rate for high-risk patients.
Fig. 2 shows time trends in the rates of PADT use by individual years. The increasing trends are all statistically significant and are similar across the three groups, although the absolute increase is greatest in the high-risk group (5.4% to 62.5%). Trends in the use of NADT use in RP, EBRT, and brachytherapy patients are shown in Fig. 3. Rates among patients receiving EBRT have risen consistently and rapidly over the study period. The rates of increase among RP and brachytherapy patients have been less consistent and less marked; the increase among brachytherapy patients is not statistically significant.
Demographic and clinical factors associated with hormonal treatment are shown in Table 3. By univariate analysis, year of diagnosis, risk, age, geographic location, education, and income were all statistically significantly associated with PADT use. Year of diagnosis, risk, age, and geographic location persisted in the multivariable analysis. Patients with intermediate and low risk disease were 1.6 (CI 1.1 to 2.1) and 6.0 (CI 4.5 to 8.0) times as likely, respectively, to receive PADT relative to low risk patients. Subgroup analysis of the three risk groups revealed that the PSA level, Gleason score, and clinical tumor stage were independently associated with PADT use for high-risk patients only; none of the three factors were associated with PADT use for low-risk patients, and only the Gleason score was associated with PADT for intermediate-risk patients.
Multiple comparisons analysis on those variables with statistically significant results in the multivariable model yielded the following results: the differences among the three risk groups were statistically significant. Patients older than 80 years of age had the highest rates of PADT use (OR 5.9, CI 3.6 to 8.5 relative to those under 60), followed by those 70–79 years old (OR 2.0, CI 1.4 to 2.9), and finally those younger than 70 years. Patients treated in the South or West were more likely to receive hormones as primary treatment than those in the East or Midwest. Patients with an annual income of $10,000 or less had higher rates of PADT use than those with annual incomes of more than $30,000.
In univariate analysis, NADT use was statistically significantly associated with year of diagnosis, risk, age, location, practice type, and income; location and income did not persist in the multivariable model. Patients with intermediate and low risk disease were 1.7 (CI 1.2 to 2.5) and 4.6 (CI 3.1 to 6.8) times as likely, respectively, to receive PADT relative to low risk patients Multiple comparisons indicated that patients older than 80 years of age were more likely to receive NADT than those younger than 70 years of age, as were patients treated in academic practices. Those with Veterans Affairs health coverage had lower rates of utilization than those with Medicare coverage (OR 0.1, CI 0.0 to 0.5). Income again tended toward a statistically significant association, with those earning $10,000 or less per year the most likely to receive NADT (OR for all other income levels 0.3 to 0.5). In an analysis by local treatment type, the higher utilization rates for NADT in the academic practices (OR 3.5, CI 2.2 to 5.4) were fully explained by EBRT patients (59.7% for EBRT patients vs. 25.4% for those in the community); the difference was not statistically significant for other primary treatments. The only factors that were consistently present on subgroup analysis of each primary treatment type were risk group and year of diagnosis.
Androgen deprivation exerts potent in vivo antitumor effects in prostate cancer (21,22). Like other prostate cancer treatments, however, hormonal ablation may also cause a range of short- and long-term side effects, which in the setting of monotherapy have been demonstrated to have a statistically significant impact on health-related quality of life relative to watchful waiting (4,23). The combination of NADT with EBRT or brachytherapy is likewise associated with impairment of some quality of life domains relative to either treatment alone (16). Furthermore, Penson et al. (24) demonstrated that stage for stage, the combination of NADT with RP or EBRT is the most expensive treatment alternative for prostate cancer, regardless of which primary treatment (RP or EBRT) is used.
PADT remains the mainstay of treatment for advanced disease: a large, recent trial (2) found a statistically significant benefit for immediate versus deferred treatment of locally advanced or metastatic prostate cancer. However, PADT has only recently been studied in localized disease. Labrie et al. (25) tested primary combined androgen blockade in 141 patients with stage T2-3 disease who refused or were ineligible for local treatment. Disease-free survival rates among the stage T3 patients were 74.6% and 53.8% at 5 and 10 years, respectively; the disease of only one stage T2 patient progressed. Azaka et al. (26) likewise treated 151 patients with stage T1-3a prostate cancer with PADT, again selecting patients ineligible for or refusing definitive treatment. They reported a 2-year progression-free survival of 43% and 62%, respectively, in stage T2b patients treated with a luteinizing hormone-releasing hormone agonist alone and with combined androgen blockade; rates were similar among T3 patients. Although these reports suggest a potential role for PADT, both studied highly selected patients, and neither compared PADT with watchful waiting, placebo, or other treatment alternatives. In a recent critical evaluation of hormonal therapy for prostate cancer, Chodak et al. (27) concluded that there is insufficient evidence to support androgen deprivation as monotherapy in localized disease.
We found that rates of PADT in high-risk patients were stable—just under 50%—over the past 5 years. However, rates among low- and intermediate-risk patients increased sharply, from 4.6% to 14.2% and from 8.9% to 19.7%, respectively. Overall, patients were nearly three times as likely to receive PADT from 1999 through 2001 as they were from 1989 through 1992. Any explanation for this trend is speculative, but it seems likely that many patients who may have opted for watchful waiting earlier are now choosing PADT, perhaps in the face of earlier and more frequent PSA testing.
We found strikingly higher rates of PADT use among low-income patients. In the short term (the first year of treatment), PADT is the least expensive treatment alternative for primary prostate cancer (24), but income was also inversely associated with the likelihood of receiving NADT, the most costly alternative. Furthermore, uninsured patients were not more likely than insured patients to receive PADT (14.9% vs. 20.5%, P = .34 by χ2 test) and were more likely than insured patients to receive NADT (25.5% vs. 9.1%, P<.001 by χ2 test). Although lower income patients had a higher level of serum PSA (P<.001), a higher Gleason sum (P<.001), and a higher tumor stage (P = .03, all by Mantel-Haenszel χ2), income was statistically significantly associated with the use of PADT, despite adjustment for risk: among low-risk patients, 19.4% of those earning less than $10,000 annually received PADT compared with 7.4% of those earning more than $75,000 annually. There is no readily apparent explanation for these observations, and so we urge that the question of socioeconomic determinants of hormonal therapy be subjected to more focused testing in the future.
We found that, since 1996, overall rates of NADT use among RP patients rose gradually, particularly among high-risk patients, of whom 16% received NADT before surgery. Although a survival advantage for immediate adjuvant hormonal therapy has been observed when lymph node involvement is found at the time of prostatectomy (29), recent data do not support androgen ablation in this neoadjuvant setting. Randomized trials over the past decade, studying a variety of regimens before RP, have consistently shown decreases in preoperative PSA levels, tumor volume, positive margin rates, and pathological stage; however, none has shown any advantage in terms of PSA-defined recurrence or survival (7–9, 30).
Soloway et al. (10) published the 5-year follow-up results from a multi-center trial in patients with clinical stage T2b prostate cancer. Their findings confirm the earlier studies that NADT decreased the positive margin rate from 48% to 18% (P<.001) but had no impact on lymph node involvement or on 5-year PSA-defined recurrence-free rates (64.8% in the NADT group compared with 67.6% in the RP only group, P = .663). Aus et al. (11) recently reported similar outcomes at 7 years of follow-up, with no difference in progression-free survival (49.8% for NADT compared with 51.5% for RP only, P = .588). Studies of prolonged NADT (8 months rather than 3 months before surgery) have suggested a greater effect in terms of preoperative and pathologic parameters (31); outcomes in terms of recurrence, however, are pending. Chodak et al. (27) argued that sufficient evidence currently exists to recommend against NADT before RP.
Rates in CaPSURE of NADT use before EBRT rose to 57%, 74%, and 90% of low-, intermediate-, and high-risk patients. Available evidence in fact demonstrates a clear benefit for this combined regimen in selected patients. In a multicenter randomized trial enrolling primarily patients with T3 or T4 prostate cancer, Bolla et al. (12) found a statistically significant overall survival advantage with the addition of goserelin to EBRT (79% vs. 62% for EBRT alone, P = .001). Two prospective trials from the Radiation Therapy Oncology Group confirmed the benefit in high-risk disease. In the RTOG 85-31 study, 977 patients were randomly assigned to EBRT with or without combined androgen blockade, and at the 4.5-year follow-up for patients with stage T3 or lymph node-positive tumors, improvements with NADT in terms of PSA-defined recurrence (16% vs. 29%, P<.001) and disease-specific survival (60% vs. 44%, P<.001) were observed. Overall survival was only improved among patients with Gleason scores of greater than 7 (66% vs. 55%, P = .03) (13).
In the RTOG 86-10 study, 471 patients with stage T3 or bulky (>25 cc) stage T2 tumors were randomly assigned to goserelin given 2 months before EBRT or to EBRT alone. With 8.6 years of follow-up, a benefit was demonstrated for NADT with respect to local control (42% vs. 30%, P = .016), PSA-defined recurrence (76% vs. 90%, P<.001), and disease-free survival (33% vs. 21%, P = .004). In contrast to RTOG 85-31, however, an overall survival benefit was demonstrated only in patients with Gleason scores less than 7 (70% vs. 52%, P = .015) (14). Intermediate- and high-risk patients planning to undergo EBRT are the only localized prostate cancer patients for whom Chodak et al. (27) found sufficient evidence to recommend routine NADT. No study has reported an advantage for EBRT with NADT in patients with lower-risk disease. The ongoing RTOG 94-08 and RTOG 94-13 studies will address this issue, as will a Canadian Uro-Oncology Group trial that is randomly assigning patients to EBRT with NADT or to hormonal therapy alone (32).
Roughly one-quarter of patients undergoing brachytherapy received NADT before implantation. Although this combination is recommended by the American Brachytherapy Society for patients with a prostate volume of greater than 60 cm3 and those with a "significant risk of disease outside the implant volume"(33), its efficacy and toxicity have not been evaluated in randomized trials. In one retrospective study, Potters et al. (15) analyzed 612 consecutive patients with prostate cancer undergoing brachytherapy, of whom 177 (29%) were treated with NADT before implantation because of a large prostate volume. Of these, 71% were effectively cytoreduced within 3 months, and 91% were cytoreduced by 8 months of therapy. However, when compared with risk-matched patients receiving brachytherapy only, 5-year PSA-defined recurrence-free rates were essentially identical: 87.1% and 86.9% in the NADT and brachytherapy-only groups (P = .935). Subgroup analysis did not identify any benefit for patients with specific risk characteristics, nor did NADT improve outcomes in patients receiving EBRT along with brachytherapy.
Potters et al. (15) concluded that the addition of NADT to brachytherapy should not be considered standard treatment, but that the cytoreductive effect of androgen ablation may decrease the toxicity associated with brachytherapy and potentially can improve dosimetry. In a follow-up study (34), however, they noted that patients who received NADT before brachytherapy had a 5-year actuarial potency rate of 52% compared with 76% for those who did not receive NADT. The effect of NADT was stronger than that of age or concurrent EBRT. Chodak et al. (27) found insufficient evidence to support this treatment combination. Because CaPSURE physicians submitting data on brachytherapy patients do report the preimplantation prostate volume, we cannot determine whether the volume was measured before or after NADT. Therefore, we cannot comment as to whether large prostate volumes or other clinical parameters are the more common determinants of NADT use in our population.
One of the great strengths of CaPSURE is that it tracks use and outcome patterns in actual practice, without the constraints imposed by clinical trial protocols. Data are collected prospectively, irrespective of any particular research question. Although the CaPSURE practice sites have not been chosen at random and, thus, cannot be assumed to represent a statistically valid sample of the United States patient population, they do represent a broad range of geographic locales and a mixture of academic and community practices. CaPSURE data are submitted only by patients and urologists; therefore, any treatments by other practitioners that are not reported by patients either to their urologists or in their questionnaires may be missed. Extant quality assurance mechanisms, including chart review of all hospital admissions, should minimize this problem. Finally, we excluded from analysis 1399 (28.9%) of 4838 otherwise eligible patients in the database because they had not yet had at least 6 months of follow-up. This criterion was established a priori, and we do not have reason to believe it introduced bias into the analysis. It is, however, possible that, with longer follow-up, the distribution of treatments, particularly for the most recent time period, may change. Despite these cautionary notes, we believe our data provide the best available description of national practice patterns.
PADT remains the core treatment for advanced prostate cancer and offers a clear benefit in specific local disease contexts. Like other treatments, however, both PADT and NADT contribute appreciably to patient morbidity, quality of life impact, and cost of care. It is not clear from evidence to date that the growing numbers of patients opting for PADT—who tend to be older and at high risk in terms of comorbidity—are likely to reap a substantial benefit, especially given the need for prolonged therapy. Extant evidence likewise does not appear to support NADT before RP or brachytherapy, and only upholds NADT before EBRT in locally advanced disease. Nonetheless, burgeoning numbers of patients with localized disease of low- and intermediate-risks are increasingly receiving both PADT and NADT. The extent to which these trends are driven by physicians, patients, or both is a question of speculation, although a multifactorial explanation seems the most likely that plausibly includes physician financial incentives, direct-to-consumer pharmaceutical advertising, and psychological imperatives on one or both sides of the examining table—to treat cancer as aggressively as possible.
The benefits of androgen ablation in advanced prostate cancer are well demonstrated, and we hope that the upward trend in use of NADT in the context of EBRT for locally advanced disease will continue. However, prospective clinical trials must clarify the efficacy of PADT compared with watchful waiting, and must identify any potential benefit to be gained from NADT in association with brachytherapy or EBRT in lower-risk disease, particularly as new agents and regimens emerge. Such trials must assess quality of life and oncologic outcomes. Updated clinical guidelines that are based on available evidence are sorely needed; these guidelines should address the optimal role of both PADT and NADT in the initial management of localized prostate cancer.
We would like to thank Vivian Weinberg, PhD, for her assistance in reviewing our statistical methods.
CaPSURE™ is supported by a grant from TAP Pharmaceutical Products, Inc., Lake Forest, IL. This research was additionally funded by National Institutes of Health/National Cancer Institute University of California-San Francisco SPORE Special Program of Research Excellence p50 c89520.
PubMed Central Canada is a service of the Canadian Institutes of Health Research (CIHR) working in partnership with the National Research Council's national science library in cooperation with the National Center for Biotechnology Information at the U.S. National Library of Medicine(NCBI/NLM). It includes content provided to the PubMed Central International archive by participating publishers.


text:
12月 19, 2014 合計視聴数:: 4645 今日は: 2
Hotel Studio 12 カリブ海諸島, Offering a private beachfront terrace, スタジオ 12 is located on the coast of St Michiel, Curaçao. This functional studio features air conditioning, free WiFi access and a kitchenette. The studio will provide you with a TV, a seating area and wonderful Caribbean Sea views. The private bathroom comes with a shower. At Studio 12 you will find an airport shuttle, an ironing service and laundry facilities. An array of activities can be enjoyed in the surroundings, including golfing, fishing and hiking. The property is a 10-minute drive from Willemstad's historic Otrobanda district. Curaçao International Airport is 9 離れたキロ. (Hotel Studio 12 Caribbean Islands hotels 予約).


text:
BODY CREME - Creme, Scrub and Soap Set ~ CONFIDENT
An effortless scent of body and soul. Light powdery musk appoints the veil of mystery and strong image.
Charm. Grace. Allure. Gratitude.
This specially formulated gift set is for anyone you believe deserves to feel the love and special treatment of being pampered. Guaranteed to cleanse away bacteria and leave your skin feeling healthy and looking new, in this gift set you will receive: 1 bar of handmade soap, 1 8oz jar of Organik Body Creme containing approx. 91% organic content, 1 8oz jar of Sugar Body Scrub, unless you prefer Dead Sea Salt Scrub and let us know by simply typing a note into the instruction box on top.


text:
4 BHK West Facing House for Sale at New Sunny Enclave
Are you tired and sick of renting? Or you are looking for a trustable place for investment? Both are satisfied here in this prestigious city, Sunny Enclave.
A comfortably built home in the center of Sunny Enclave with all peace and silence even though in the heart of busy city - awaiting you with all prestige and luxuries. This Newly Built home has 4 spacious bedrooms attached washrooms, living, dining, kitchen, balconies and amazing interiors with all comfort features included.
The house is facing West with all location advantages as well as natural blessings, plenty of air and light and a very dignified and friendly community around.
Built up area: 128 Sq Yards
Wide space in front for parking, gardening, spacious balconies, and utility terrace
Please contact us for more details regarding possession of this Loving Home
Thanks & Regards
GURU ESTATES SCO. No 31, Mega market, Sector 125, New Sunny Enclave, Mohali
Mob: 8054410005
4 BHK 128 gaj West Facing Home at New Sunny Enclave
India, Punjab, Mohali
Published 1 year ago
7100000.00 Rs
4 BHK 128 gaj West Facing Home at New Sunny Enclave
India, Punjab, Mohali,
Published 1 year ago
Contact seller
Question? Need more information? Want to ask question? Add new comment...
Ask questions related to this listing only.
Comments are moderated.


text:
Scott McElroy
Editor, Team
Scott McElroy is a video editor, motion graphics artist and animator. In 2011, he edited and co-wrote the documentary High Ground. The film tells the story of 11 wounded Iraq and Afghanistan war veterans who attempt to climb a 20,000ft. peak in the Himalayas. The film was directed by Michael Brown and produced by Don Hahn, producer of the Disney classics The Lion King and Beauty and the Beast. The film premiered at the 2012 Boulder International Film Festival and won the Best Call 2 Action Award and the coveted People's Choice Award.
Scott is the chief editing officer and owner of Thought/Process Films and believes filmmaking is equal parts thought and process. He lives in Longmont, CO with his wife Bess and daughter Olive.


text:
THEATER; Dana Ivey's Penchant for the Persnickety
Published: August 2, 1987
(Page 2 of 2)
The character was based on an amalgam of Mr. Urhy's grandmother, his grandmother's sisters and his mother. But despite the intimacy of his conceptions, the playwright feels that Miss Ivey supplied him with new insights on his own background. ''Dana has helped me see how really vulnerable this lady is, how you can't be that tight and that unbending without being susceptible underneath. She makes me see a lot that I didn't see as a boy. These are not sentimental people. These are not people who say, 'I love you,' even to their own children. But Dana has enabled me to see, for the first time, how much feeling was really there that wasn't being demonstrated.''
One of the aspects that has distinguished the actress's career is her portrayal of such a wide range of characters. ''I'm a repertory actor,'' said Miss Ivey with pride, ''an old-fashioned product of the theater where you play one character one week and another character the next. The greatest compliment is that nobody ever recognizes you. Whereas in our valueless culture, the highest praise seems to be the star thing and constant recognition, my background is that you should create something that is so itself that nobody realizes it's you even if they saw you last week as someone else. That's the exciting part of it for me.''
Mr. Gray sees the habit of categorizing actors as a problem in general, but one that has particular significance for Miss Ivey. ''I think one of the things that people are likely to say about Dana is that she's wonderfully rich in the way in which she explores seeming drabness,'' he said. ''And people are likely to go on casting her in that mold which I think is a great pity, because quite clearly she's an actress who can cover the spectrum. I mean you can't do what she does as well as she does it unless you are an actress of enormous range.'' ''Probably I have in me,'' explained Miss Ivey, ''a capacity for seeing a lot of sides of life, and I seem to be able to tap into the things that make these antagonists successful. It may be because I'm not afraid of the dark side of life since I know it, I've come to terms with it myself, and I'm willing to portray it.''
Miss Ivey's experience of the ''dark side'' was most pronounced when she was afflicted with bouts of Guillain-Barre syndrome, a viral disease that strikes the muscular and nervous systems and that left her semi-paralyzed for two separate four-month periods, in 1969 and 1973. ''I had some quite fearful moments when I thought I was going to be a vegetable for the rest of my life,'' she recalled. ''I knew that there was a lesson in it, and that I probably wouldn't start to get well until I had somehow begun to learn what that lesson was.''
In the larger sense, Miss Ivey's training as an actress has been occurring her whole life. Her mother, Mary Nell Santacroce, is an Atlanta-based actress who directed drama and taught in the theater department at Georgia Tech. Miss Ivey (no relation, by the way, to another relative newcomer, Judith Ivey) received her more official training on a Fulbright scholarship at the London Academy of Music and Dramatic Arts in the mid-60's.
After years of performing in resident and repertory situations - at the Alliance Theater in Atlanta, the Shaw Festival in Canada, the Hartford Stage Company, the Mark Taper Forum in Los Angeles and even the Alaska Repertory - Miss Ivey moved to New York in 1977. She enraged audiences as the villainous Miss Millie in Steven Spielberg's film version of ''The Color Purple,'' and she has recently completed the TV series, ''Easy Street,'' in which she portrayed the snooty sister-in-law Eleanor.
''In the last six months something has been carrying me along to a new and somehow different position,'' mused Miss Ivey. ''I met one girl at a party who said, 'Oh, Miss Ivey, it's such a pleasure to meet you.' She told me that she included my name on an application for Julliard as an actress who inspired her. But the upshot was that she didn't get in. So I still have to wonder what it all means.''
Photos of Dna Ivey as herself and as ''Miss Daisy'' (Cori Wells Braun; Jack Mitchell); photo of Dana Ivey as Melanie Garth in ''Quartermaine's Terms'' (Willaim B. Carter) (page 14)


text:
9.8 / 10 based on 3 reviews.
Of the 3 people who reviewed this product 100% would recommend it.
Expert Staff Review:
There are definitely more things to like than not to like with the Phoenix Titan 1282e. The fire protection and insurance rating offered make this a decent option for home use or even the office for keeping low amounts of cash or paperwork protected from fire. Read my full review here.
Firstly the safe looks amazing and it's amazingly easy to operate.
I like the fact that it's really well made and the security features completely fit the purpose for which it's made. I think it's going to last us a lifetime and wouldn't be surprised if my grandchildren pass it on to their loved ones either!
In a nutshell robbers be aware you and not going to drag in far without a slipped disc and pain in the back to recon with!
I would like to take this opportunity to let you know that lm so pleased l got the safe from you for some reason l feel everything is safe now (sorry about the pun) one big problem though is that everytime l have tried to register the guarantee the site WONT let me lv got so fed up trying that lv just let it go, the depth of the safe is a good length so l dont have to fold documents in half overall lm pleased & thats all that matters


text:
Edward Bond (October 1844 – 18 August 1920) was a barrister and Conservative Party politician.
Educated at Merchant Taylors School and St John's College, Oxford University, he was resident at Elm Bank, Hampstead, where he became a member of the library commissioners. He was called to the bar in 1871.
He was a member of the London School Board elected in 1882 for Marylebone, he resigned in April 1884 when he was appointed an Assistant Charity Commissioner. He held the office until 1891.
In March 1895 he was elected to the London County Council as a Moderate Party councillor for Hampstead. He was re-elected for a second term in 1898, remaining on the council until 1901.
In the meantime he had been chosen as Conservative parliamentary candidate at Nottingham East. He was elected to the House of Commons at the 1895 general election, holding the seat until 1906.
- "Obituary: Mr. Edward Bond". The Times: p. 13. 20 August 1920.


text:
It doesn't matter if you are in Braunschweig privately, on business or as a tourist – we are always here to help and advise you. With our support, your plans will definitely succeed. As the tourist centre for Braunschweig we have all the information about the city and its ambience at hand – from arrival and commerce, catering and culture to city tours and accommodation. Don't hesitate to use our service to make your stay as relaxed and individual as possible. Trust our commitment to turn your stay in Braunschweig into a successful and unforgettable experience.
We are looking forward to your visit!
Our Touristinfo is right in the 'heart' of Braunschweig, near at the historical Burgplatz.
From the central train station to the stop 'Rathaus'
Metro lines (trams): M1, Tram 2
Bus line: 420
and then only a 3 minute walk
From the central train station to the stop 'Schloss'
Metro lines (tram): M1, Tram 2, M5
Bus lines: 420, 730
and then only a 3 minute walk
If you are coming by car it is best to use the multi-storey car park Packhof.
Our service:
The Touristinfo offers you a huge choice of tickets for (nearly) every type of event or performance. You will find a suitable event for every taste and every age group.
Our own personal service for you: a present that is always right: the ticket voucher.
Tourist Information
Braunschweig Stadtmarketing GmbH
Kleine Burg 14
38100 Braunschweig
|++49 5 31 / 4 70-20 40
|++49 5 31 / 4 70-20 44
|Opening Hours
|Mon. - Fri. 10:00am - 6:30pm
Sat. 10:00am - 4:00pm
from 1st May to 30th September also:
Sun. 10:00am - 12:00am